Application of a new Enteral Formula adding taurine and L-carnitine in patients with severe neurological disease

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17013909

Enrollment

Unknown

Registered

2017-12-14

Start date

2017-12-15

Completion date

Unknown

Last updated

2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe neurological disease

Interventions

A group:feeding JEVITY

B group:feeding Ensure

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients admitted to the ICU will be assessed for eligibility on the day of admission. Inclusion criteria: 1. Aged =18 years; 2. APACHE II score =10; 3. Estimated Enteral Nutrition Support Clinically =5 days; 4. First admission Diagnosis of neurological disorders: craniocerebral trauma, intracerebral hemorrhage, Cerebral infarction, hypoxic-ischemic encephalopathy and so on; 5. GCS=12.

Exclusion criteria

Exclusion criteria: Allergy to any component of the nutritional formula, contraindications to the use of nutritional formulas (including active gastrointestinal bleeding, paralytic ileus, acute severe pancreatitis and other unsuitable diseases for enteral nutrition), hemodynamic instability.

Design outcomes

Primary

Measure	Time frame
CD4+/CD8+;	—

Secondary

Measure	Time frame
Laboratory examinations(blood routine, liver and kidney function, CRP, glucose);IL-8;IL-6;CD28;TIM3;PD-1;TNFa;	—

Countries

China

Contacts

Public ContactRongqing Sun

First Affiliated Hospital of Zhengzhou University

rongqing.sun@126.com+86 13838082866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 14, 2026